Trial Profile
Phase II Trial of Gemcitabine and Genistein in Metastatic Breast Cancer Patients With Biomarker Assays.
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 26 Jun 2023
Price :
$35
*
At a glance
- Drugs Gemcitabine (Primary) ; Genistein (Primary)
- Indications Advanced breast cancer
- Focus Biomarker; Therapeutic Use
- 13 Mar 2012 Additional lead trial investigator (Amy Weise) identified as reported by ClinicalTrials.gov.
- 13 Mar 2012 Actual patient number is 19 according to ClinicalTrials.gov.
- 10 Nov 2009 Actual end date (Oct 2009) added as reported by ClinicalTrials.gov.